Poster Presentations

2017 ASHP Midyear Clinical Meeting

4-096 – Establishing a Beyond Use Date for Compounded Haloperidol Oral Suspension Prepared from Tablets Using a Novel Automated Wet-Milling Technology

4-137 – Using Automation to Eliminate Exposure to Aerosolized Powders During the Compounding of Oral Liquids

2017 AAPS Annual Meeting and Exposition (San Diego)

W3006 – New Accelerated Oxidative Stress Method for Assessing Oxidation of Active Pharmaceutical Ingredients and Drug Products

2015 AAPS Annual Meeting and Exposition (Orlando)

T3076 – Sterilization Process Development for pre-Operative Antiseptic Products

68th Annual Meeting of the American Epilepsy Society 2014 (Seattle)

1.324 – Bioequivalence Testing of Disparate Generic Lamotrigine Products using Chronic Dosing in People with Epilepsy: the EQUIGEN Study

2.285 – Patients Reporting Problems after Generic Antiepilepltic Drug Switches are Unlikely to Participate in a Generic Bioequivalence Trial

2.286 – Subject-unrecognized Medication Adherence Errors in the Equivalence Among Generic AED (EQUIGEN) Chronic Dose Trial

2.287 – Equivalence Among Generic AEDs (EQUIGEN) – Single Dose Study

67th Annual Meeting of the American Epilepsy Society 2013 (Washington, DC)

1.229 – Identification of the Most Disparate Generic Lamotrigine Tablets based on in vitro Screening

3.212 – Comparison of Bioavailability and Dissolution Data for Generic Lamotrigine Tablets in the EQUIGEN Trial

2013 AAPS Annual Meeting and Exposition (San Antonio)

T3385 – Establishing a Beyond Use Date for Compounded Marbofloxacin Oral Suspension

W5004 – Defining Processes to Manufacture Sterile Antiseptics

W5334 – Determination of in vitro Criteria to Select the Most Disparate Generic Lamotrigine Tablets

2012 AAPS Annual Meeting and Exposition (Chicago)

T3246 – Optimizing Small Scale Nanomilling Process Parameters for Genistein

T3280 – Establishing a Beyond Use Date for Compounded Norfloxacin Oral Suspension

W5189 – Prediction of Drug Solubility in Lipid Mixtures from the Individual Ingredients

2011 AAPS Annual Meeting and Exposition (Washington, DC)

T3172 – Optimizing Small Scale Nanomilling Process Parameters for Genistein

W4319 – Physicochemical Characterization of Lupeol and Development of a Preclinical Formulation for Oral Administration

2010 Pharmaceutical Sciences World Congress (PSWC) / American Association of Pharmaceutical Scientists (AAPS) Meeting & Exposition: (New Orleans)

M1269 – Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture (published in HospPharm 2010; 45(10):779-784 / doi:10.1310/hpj4510-779)

M1270 – Re-Testing of Stockpiled Drug Products for Emergency Use to Extend Shelf Life